Key triggers in Sampre Nutritions (as per latest publicly available information up to Feb 2026):

1. Multiple long‑term manufacturing contracts (domestic + international)

- 3‑year manufacturing agreement with Reliance Consumer Products Ltd (RCPL) for confectionery and nutraceutical/food products; expected annual business of about ₹12–15 crore for 3 years. (tradebrains.in)

- 3‑year manufacturing agreement with Tolaram Wellness Ltd, Nigeria, expected to generate about ₹10 crore per year (₹30 crore over 3 years). (tradebrains.in)

- 3‑year contract with Rama Exports for nutraceutical and food products, projected at ₹15 crore over the tenure. (moneycontrol.com)

- Earlier manufacturing agreement with PRAN Beverages (India), where from 1 Aug 2024 the company expected orders of ~200 tons/month and ~₹3 crore monthly revenue (i.e. ~₹30 crore p.a.) for FY25. (in.investing.com)

These contracts give medium‑term volume and revenue visibility, which the market tends to treat as a major trigger.

2. Aggressive international expansion – especially Egypt & Africa

- Wholly‑owned subsidiary Sampre Nutrition Holding Ltd signed a Land Purchase & Allocation Agreement (1 Feb 2026) with Orascom Industrial Parks, Egypt, for 30,000 sq.m. industrial land to set up a food processing and confectionery facility. This is meant to boost production and support long‑term global growth. (tradebrains.in)

- Board approval to raise about ₹355 crore via FCCBs (foreign currency convertible bonds), primarily to fund expansion in Egypt and Liberia and strengthen presence in high‑growth international FMCG markets. (angelone.in)

This combination of capex + funding is a key structural trigger, but it also adds execution and forex/dilution risk.

3. Sharp improvement in earnings momentum (FY26 so far)

- Q1 FY26 (Apr–Jun 2025):

- Revenue: ₹10.87 crore, up from ₹4.51 crore YoY (≈ +141%).

- Net profit: ₹70.76 lakh, up from ₹9.89 lakh (multi‑fold / ~+615%). (theprint.in)

- Q2 FY26:

- Revenue: ₹9.99 crore, up 37.5% YoY (₹7.27 crore → ₹9.99 crore).

- Net profit: ₹89.55 lakh, ~620% YoY (₹12.45 lakh → ₹89.55 lakh). (angelone.in)

- H1 FY26 (Q1+Q2): revenue ₹20.86 crore (+77% YoY) and net profit ₹1.60 crore (>6x YoY). (angelone.in)

Sustained high growth, especially coming after a weaker FY24, is a strong near‑term sentiment trigger.

4. Shareholder‑friendly corporate actions & balance sheet moves

- Stock split + bonus (announced 19 Sep 2025):

- Split from face value ₹10 to ₹5 (10:5 split) and 1:1 bonus issue (one bonus share for each share held). Ex‑date was 11 Nov 2025. (swastika.co.in)

- Conversion of 550,000 warrants into equity shares, increasing promoter stake and equity base. (angelone.in)

- Preferential issue by converting existing unsecured loans of promoters into equity (noted in later exchange updates). (m.dailyhunt.in)

These actions typically improve liquidity, signal management confidence, and are seen as triggers for higher retail participation, though they don’t change intrinsic value by themselves.

5. Client profile and positioning in confectionery / nutraceuticals

- Core business in sugar confectionery and centre‑filled products (eclairs, candies, lollipops, toffees, etc.).

- Supplies to well‑known FMCG names like Mondelez India, Nestlé, Perfetti Van Melle, Reliance, DS Group, as per recent disclosures. (theprint.in)

- Recent shift to also scale nutraceutical and food products, supported by the RCPL, Tolaram and Rama Exports contracts. (tradebrains.in)

6. Key risks that can work as negative triggers (for context)

- Successful commissioning and ramp‑up of the Egypt facility is critical; delays or cost overruns could hurt returns on the new capex. (tradebrains.in)

- High dependence on a few large clients / contracts (RCPL, Tolaram, Rama, PRAN, etc.) means loss or downsizing of any one contract can impact revenues disproportionately. (tradebrains.in)

- FCCB issue introduces forex and dilution risk if the share price underperforms or currency moves unfavourably. (angelone.in)

---

Concise summary:

Sampre Nutritions has moved from being a small confectionery contract manufacturer to positioning itself as a niche FMCG/nutrition player with visible order book from multiple 3‑year manufacturing contracts (RCPL, Tolaram Nigeria, Rama Exports, earlier PRAN). This has translated into very strong revenue and profit growth in FY26 so far, after a weaker FY24. Parallelly, the company is attempting a step‑change in scale via overseas expansion (new Egypt facility, focus on Africa) funded partly through a ₹355 crore FCCB issue and backed by bonus + split + promoter capital infusions.

Market participants largely treat (a) execution of these contracts, (b) progress on the Egypt capex, and (c) sustainability of current high growth as the key fundamental triggers for the stock—not recommendations, but factors to track closely in filings and quarterly results.

For the most accurate and latest updates, please refer to the company’s filings on the BSE/NSE and its investor‑relations page (sampreltd.com).

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com